Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. The company's product candidate is sacituzumab govitecan (IMMU-132), an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer who previously received at least two prior therapies for metastatic disease. The company also has other product candidates, which target solid tumors and hematologic malignancies in various stages of clinical and preclinical development, such as labetuzumab govitecan that binds the CEACAM5 antigen expressed on CRC and other solid cancers, and IMMU-140 for the treatment of hematologic malignancies.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.